Schizophrenia: Remission, Recovery, and Long-acting Injectable (LAI) Antipsychotics

This activity is sponsored by the College of Psychiatric and Neurologic Pharmacists (CPNP) and Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from Janssen Pharmaceuticals, Inc and Alkermes, Inc.

FACULTY

Carol A. Ott, PharmD, BCPP
Clinical Associate Professor
Department of Pharmacy Practice
Purdue University College of Pharmacy
West Lafayette, Indiana
Clinical Pharmacy Specialist, Psychiatry
Eskenazi Health/Midtown Community Mental Health
Indianapolis, Indiana

FINANCIAL DISCLOSURE

Carol A. Ott, PharmD, BCPP, has indicated that she has no relevant affiliations or financial relationships with a commercial interest to disclose.

The following reviewer, Mary C. Borovicka, PharmD, BCPS, BCPP, hereby states that he does not have any financial relationships or relationships to products or devices with a commercial interest related to the content of this activity. This reviewer has confirmed that this activity is evidence-based and does not contain commercial bias.

Brenda Schimenti, MS, Susanne Batesko, RN, BSN, Michele Salernitano, and Robin Carrino, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of College of Psychiatric and Neurologic Pharmacists (CPNP) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. CPNP is committed to providing participants with a quality learning experience and to improving clinical outcomes without promoting the financial interests of a proprietary business.

ACCREDITATION STATEMENTS

PHARMACY
acpeThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0284-9999-15-080-H01-P
Credits:
1.5 hour (0.15 ceu)

Published: October 8, 2015
Expires: October 8, 2017
Type of Activity: Knowledge
Media: Internet

Fee Information: There is no fee for this educational activity.

Estimated time to complete activity: 90 minutes

TARGET AUDIENCE

This accredited activity has been designed for pharmacists.

HOW TO OBTAIN CREDIT

During the period October 8, 2015 through October 8, 2017, participants must 1) read the learning objectives and faculty disclosures; 2) review the full content of the educational activity; and 3) complete the posttest and the evaluation form. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on Submit Posttest at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.

GOAL

This activity is designed to help pharmacists acquire a higher level of expertise about schizophrenia. Focus is placed on the role of the pharmacist in providing recommendations for improving patient outcomes as well as how the pharmacist can motivate patients to medication plan adherence as a critical piece to remission and recovery. The importance of the pharmacist in identifying emerging adverse reactions, drug interactions, and/or patient nonadherence to therapy in order to communicate these events to appropriate health care team members is addressed.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants should be better able to:

  1. Describe the signs and symptoms of schizophrenia and the impact on patients' lives;
  2. Explain what constitutes remission and recovery in patients receiving treatment for schizophrenia and the importance of treatment adherence;
  3. Assess the safety, pharmacokinetic, and pharmaceutical properties of long-acting injectable (LAI) antipsychotics when optimizing medication profiles for patients with schizophrenia; and
  4. Identify strategies to implement in pharmacist-patient encounters to achieve treatment adherence and optimal patient outcomes.

REQUIRED COMPUTER HARDWARE/SOFTWARE

Please ensure the computer you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft Powerpoint, Flash Player & HTML5

DISCLOSURE OF UNLABELED USE AND DISCLAIMER

It is the policy of CPNP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.

Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by CPNP for any product or manufacturer identified.

This educational activity does not contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA).